Literature DB >> 27418640

CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency.

Bernice Lo1, Jill M Fritz2, Helen C Su3, Gulbu Uzel4, Michael B Jordan5, Michael J Lenardo2.   

Abstract

CTLA-4 is a critical inhibitory "checkpoint" molecule of immune activation. Several recent reports have described patients with immune dysregulation and lymphoproliferative disease resulting from 2 different genetic diseases that directly or indirectly cause CTLA-4 deficiency. Numerous articles have also been published describing CTLA-4 blockade in cancer immunotherapy and its side effects, which are ultimately the consequence of treatment-induced CTLA-4 deficiency. Here, we review these 2 diseases and CTLA-4 blockade therapy, emphasizing the crucial role of CTLA-4 in immune checkpoint regulation.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27418640      PMCID： PMC5000841          DOI： 10.1182/blood-2016-04-712612

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  48 in total

1.  Exocytosis of CTLA-4 is dependent on phospholipase D and ADP ribosylation factor-1 and stimulated during activation of regulatory T cells.

Authors:  Karen I Mead; Yong Zheng; Claire N Manzotti; Laura C A Perry; Michael K P Liu; Fiona Burke; Dale J Powner; Michael J O Wakelam; David M Sansom
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

2.  SEL-2, the C. elegans neurobeachin/LRBA homolog, is a negative regulator of lin-12/Notch activity and affects endosomal traffic in polarized epithelial cells.

Authors:  Natalie de Souza; Laura G Vallier; Hanna Fares; Iva Greenwald
Journal:  Development       Date:  2007-01-10       Impact factor: 6.868

3.  Identification of a novel lipopolysaccharide-inducible gene with key features of both A kinase anchor proteins and chs1/beige proteins.

Authors:  J W Wang; J Howson; E Haller; W G Kerr
Journal:  J Immunol       Date:  2001-04-01       Impact factor: 5.422

4.  Identification and distribution of the costimulatory receptor CD28 in the mouse.

Authors:  J A Gross; E Callas; J P Allison
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

5.  Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells.

Authors:  Robert Zeiser; Dennis B Leveson-Gower; Elizabeth A Zambricki; Neeraja Kambham; Andreas Beilhack; John Loh; Jing-Zhou Hou; Robert S Negrin
Journal:  Blood       Date:  2007-10-29       Impact factor: 22.113

6.  The interaction properties of costimulatory molecules revisited.

Authors:  Alison V Collins; Douglas W Brodie; Robert J C Gilbert; Andrea Iaboni; Raquel Manso-Sancho; Björn Walse; David I Stuart; P Anton van der Merwe; Simon J Davis
Journal:  Immunity       Date:  2002-08       Impact factor: 31.745

7.  Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.

Authors:  S Read; V Malmström; F Powrie
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

8.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.

Authors:  Manuela Battaglia; Angela Stabilini; Maria-Grazia Roncarolo
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

9.  Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients.

Authors:  Manuela Battaglia; Angela Stabilini; Barbara Migliavacca; Jutta Horejs-Hoeck; Thomas Kaupper; Maria-Grazia Roncarolo
Journal:  J Immunol       Date:  2006-12-15       Impact factor: 5.422

10.  Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals.

Authors:  Susan Moir; Jason Ho; Angela Malaspina; Wei Wang; Angela C DiPoto; Marie A O'Shea; Gregg Roby; Shyam Kottilil; James Arthos; Michael A Proschan; Tae-Wook Chun; Anthony S Fauci
Journal:  J Exp Med       Date:  2008-07-14       Impact factor: 14.307
View more
  42 in total

1.  Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency.

Authors:  Ayca Kiykim; Ismail Ogulur; Esra Dursun; Louis Marie Charbonnier; Ercan Nain; Sukru Cekic; Dilek Dogruel; Neslihan Edeer Karaca; Mujde Tuba Cogurlu; Ozlem Arman Bilir; Murat Cansever; Hasan Kapakli; Dilek Baser; Nurhan Kasap; Seyhan Kutlug; Derya Ufuk Altintas; Ahmad Al-Shaibi; Nourhen Agrebi; Manolya Kara; Ayla Guven; Ayper Somer; Cigdem Aydogmus; Nuray Aktay Ayaz; Ayse Metin; Metin Aydogan; Aysen Uncuoglu; Turkan Patiroglu; Alisan Yildiran; Sukru Nail Guner; Sevgi Keles; Ismail Reisli; Guzide Aksu; Necil Kutukculer; Sara S Kilic; Mustafa Yilmaz; Elif Karakoc-Aydiner; Bernice Lo; Ahmet Ozen; Talal A Chatila; Safa Baris
Journal:  J Allergy Clin Immunol Pract       Date:  2019-06-22

Review 2.  Checkpoint Inhibitors: Applications for Autoimmunity.

Authors:  Anna S Tocheva; Adam Mor
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-27       Impact factor: 4.806

3.  Cerebral Lymphoproliferation in a Patient with Kabuki Syndrome.

Authors:  Antonio Marzollo; Davide Colavito; Stefano Sartori; Giuseppe Nicolò Fanelli; Maria Caterina Putti
Journal:  J Clin Immunol       Date:  2018-05-30       Impact factor: 8.317

Review 4.  Common variable immune deficiency: Dissection of the variable.

Authors:  Charlotte Cunningham-Rundles
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

5.  Neurological Involvement in Childhood Evans Syndrome.

Authors:  Thomas Pincez; Bénédicte Neven; Hubert Ducou Le Pointe; Pascale Varlet; Helder Fernandes; Albane Gareton; Guy Leverger; Thierry Leblanc; Hervé Chambost; Gérard Michel; Marlène Pasquet; Frédéric Millot; Olivier Hermine; Alexis Mathian; Marie Hully; Hélène Zephir; Mohamed Hamidou; Jean-Marc Durand; Yves Perel; Judith Landman-Parker; Fréderic Rieux-Laucat; Nathalie Aladjidi
Journal:  J Clin Immunol       Date:  2019-01-22       Impact factor: 8.317

6.  Primary immunodeficiencies: novel genes and unusual presentations.

Authors:  Luigi D Notarangelo; Gulbu Uzel; V Koneti Rao
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

7.  Immunological phenotype of the murine Lrba knockout.

Authors:  Laura Gámez-Díaz; Julika Neumann; Fiona Jäger; Michele Proietti; Felicitas Felber; Pauline Soulas-Sprauel; Lisa Perruzza; Fabio Grassi; Tamara Kögl; Peter Aichele; Manfred Kilimann; Bodo Grimbacher; Sophie Jung
Journal:  Immunol Cell Biol       Date:  2017-07-25       Impact factor: 5.126

Review 8.  How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation.

Authors:  Roshini S Abraham
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 9.  Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.

Authors:  Kristen E Pauken; Michael Dougan; Noel R Rose; Andrew H Lichtman; Arlene H Sharpe
Journal:  Trends Immunol       Date:  2019-04-30       Impact factor: 16.687

Review 10.  Diagnostic Tools for Inborn Errors of Human Immunity (Primary Immunodeficiencies and Immune Dysregulatory Diseases).

Authors:  Annely M Richardson; Ann M Moyer; Linda Hasadsri; Roshini S Abraham
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-22       Impact factor: 4.806
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.